Effect of methotrexate discontinuation on efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis: A randomised clinical trial

Annals of the Rheumatic Diseases

Volumn 76, Issue 9, 2017, Pages 1559-1565

  Park, Jin Kyun ^a   Lee, Min Ah ^a   Lee, Eun Young ^a   Song, Yeong Wook ^a   Choi, Yunhee ^b   Winthrop, Kevin L ^c   Lee, Eun Bong ^a  

^a Seoul National University   (South Korea)

^b Seoul National University Hospital   (South Korea)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

influenza.; methotrexate; Rheumatoid arthritis; vaccination

Indexed keywords

ABATACEPT; GC FLU; INFLUENZA VACCINE; METHOTREXATE; PARACETAMOL; PREDNISOLONE; RITUXIMAB; TOCILIZUMAB; TOFACITINIB; TUMOR NECROSIS FACTOR INHIBITOR; VIRUS ANTIBODY; ANTIRHEUMATIC AGENT;

ADULT; ANTIBODY TITER; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DAS28; DISEASE ACTIVITY; DIZZINESS; FEMALE; FRACTURE; HEADACHE; HUMAN; IMMUNOGENICITY; INJECTION SITE REACTION; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PARALLEL DESIGN; PATIENT SATISFACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; UPPER RESPIRATORY TRACT INFECTION; VACCINATION; AGED; ARTHRITIS, RHEUMATOID; DEPRESCRIPTION; DRUG ADMINISTRATION; IMMUNOLOGY; INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H3N2); INFLUENZA B VIRUS; INFLUENZA, HUMAN; MIDDLE AGED; TIME FACTOR; VACCINE IMMUNOGENICITY;

AGED; ANTIBODIES, VIRAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DEPRESCRIPTIONS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOGENICITY, VACCINE; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; METHOTREXATE; MIDDLE AGED; TIME FACTORS;

EID: 85028283541     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2017-211128     Document Type: Article

References (25)

1. Doran MF, Crowson CS, Pond GR, et al. Frequency of infection in patients with rheumatoid arthritis compared with controls: A population-based study. Arthritis Rheum 2002;46:2287-93.
2. Au K, Reed G, Curtis JR, et al. High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. Ann Rheum Dis 2011;70:785-91.
3. Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762-84.
4. van Assen S, Agmon-Levin N, Elkayam O, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2011;70:414-22.
5. Singh JA, Saag KG, Bridges SL, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 2016;68:1-26.
6. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492-509.
7. Winthrop KL, Silverfield J, Racewicz A, et al. The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis. Ann Rheum Dis 2016;75:687-95.
8. Kapetanovic MC, Saxne T, Nilsson JA, et al. Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients. Rheumatology 2007;46:608-11.
9. Kapetanovic MC, Kristensen LE, Saxne T, et al. Impact of anti-rheumatic treatment on immunogenicity of pandemic H1N1 influenza vaccine in patients with arthritis. Arthritis Res Ther 2014;16:R2.
10. Ribeiro AC, Guedes LK, Moraes JC, et al. Reduced seroprotection after pandemic H1N1 influenza adjuvant-free vaccination in patients with rheumatoid arthritis: Implications for clinical practice. Ann Rheum Dis 2011;70:2144-7.
11. Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 2012;64:625-39.
12. World Medical Association. World Medical Association declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA 2013;310:2191-4.
13. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
14. Hannoun C, Megas F, Piercy J. Immunogenicity and protective efficacy of influenza vaccination. Virus Res 2004;103:133-8.
15. van der Maas A, Lie E, Christensen R, et al. Construct and criterion validity of several proposed DAS28-based rheumatoid arthritis flare criteria: An OMERACT cohort validation study. Ann Rheum Dis 2013;72:1800-5.
16. Hua C, Barnetche T, Combe B, et al. Effect of methotrexate, anti-tumor necrosis factor ?, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: A systematic review and meta-analysis. Arthritis Care Res 2014;66:1016-26.
17. McMahan ZH, Bingham CO. Effects of biological and non-biological immunomodulatory therapies on the immunogenicity of vaccines in patients with rheumatic diseases. Arthritis Res Ther 2014;16:506.
18. Garcês S, Demengeot J, Benito-Garcia E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: A systematic review of the literature with a meta-analysis. Ann Rheum Dis 2013;72:1947-55.
19. Dalrymple JM, Stamp LK, O'Donnell JL, et al. Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 2008;58:3299-308.
20. Thornton CC, Al-Rashed F, Calay D, et al. Methotrexate-mediated activation of an AMPK-CREB-dependent pathway: A novel mechanism for vascular protection in chronic systemic inflammation. Ann Rheum Dis 2016;75:439-48.
21. Gerards AH, de Lathouder S, de Groot ER, et al. Inhibition of cytokine production by methotrexate. studies in healthy volunteers and patients with rheumatoid arthritis. Rheumatology 2003;42:1189-96.
22. Nesher G, Moore TL. The in vitro effects of methotrexate on peripheral blood mononuclear cells. modulation by methyl donors and spermidine. Arthritis Rheum 1990;33:954-9.
23. Taubenberger JK, Morens DM. Influenza: The once and future pandemic. Public Health Rep 2010;125(Suppl 3):15-26.
24. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005;352:2271-84.
25. Ohmit SE, Petrie JG, Cross RT, , et al. Influenza hemagglutination-inhibition antibody titer as a correlate of vaccine-induced protection. J Infect Dis 2011;204:1879-85.